Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.

Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, Jonas BA, Keegan THM.

Cancer. 2018 Feb 16. doi: 10.1002/cncr.31296. [Epub ahead of print]


Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA.

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.


Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia.

Kjelland JD, Dwyre DM, Jonas BA.

Case Rep Hematol. 2017;2017:3625946. doi: 10.1155/2017/3625946. Epub 2017 Oct 11.


Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance.

Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, Jonas BA.

Blood Cancer J. 2017 Sep 8;7(9):e605. doi: 10.1038/bcj.2017.81.


On the origin of relapse in AML.

Jonas BA.

Sci Transl Med. 2017 Jul 12;9(398). pii: eaan8205. doi: 10.1126/scitranslmed.aan8205.


A new therapeutic target for myelofibrosis is cause for Gli.

Jonas BA.

Sci Transl Med. 2017 May 31;9(392). pii: eaan4297. doi: 10.1126/scitranslmed.aan4297.


Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, Keegan THM.

Br J Haematol. 2017 Jul;178(1):72-80. doi: 10.1111/bjh.14638. Epub 2017 May 25.


Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check.

Jonas BA.

Sci Transl Med. 2017 Apr 19;9(386). pii: eaan2781. doi: 10.1126/scitranslmed.aan2781.


Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.

Ho G, Jonas BA, Li Q, Brunson A, Wun T, Keegan THM.

Br J Haematol. 2017 Jun;177(5):791-799. doi: 10.1111/bjh.14631. Epub 2017 Apr 17.


From MDS/AML to iPSC and back again.

Jonas BA.

Sci Transl Med. 2017 Mar 8;9(380). pii: eaam9861. doi: 10.1126/scitranslmed.aam9861.


Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach.

Jonas BA, Medeiros BC.

Oncology (Williston Park). 2016 Apr;30(4):330, 333. No abstract available.


Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome.

Ali SF, Sonu RJ, Dwyre DM, Jonas BA, Rashidi HH.

Case Rep Hematol. 2015;2015:318545. doi: 10.1155/2015/318545. Epub 2015 Dec 21.


Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis.

Stelling A, Jonas BA, Rashidi HH, Abedi M, Chen M.

Cancers (Basel). 2015 Dec 14;7(4):2459-65. doi: 10.3390/cancers7040903.


B lymphoblastic leukemia with granules mimicking acute myeloid leukemia.

Song JY, Khojeini EV, Dwyre DM, Jonas BA.

Int J Hematol. 2015 Sep;102(3):251-2. doi: 10.1007/s12185-015-1842-9. Epub 2015 Jul 18. No abstract available.


Optimal Molecular Methods in Detecting p190 (BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature.

Sonu RJ, Jonas BA, Dwyre DM, Gregg JP, Rashidi HH.

Case Rep Hematol. 2015;2015:458052. doi: 10.1155/2015/458052. Epub 2015 Apr 8.


Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer.

McCoach CE, Rogers JG, Dwyre DM, Jonas BA.

Cancer Treat Commun. 2015;4:15-18. No abstract available.


MDS prognostic scoring systems – past, present, and future.

Jonas BA, Greenberg PL.

Best Pract Res Clin Haematol. 2015 Mar;28(1):3-13. doi: 10.1016/j.beha.2014.11.001. Epub 2014 Nov 11. Review.


Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.

Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX.

Nanomedicine (Lond). 2014;9(12):1807-20. doi: 10.2217/nnm.14.44. Epub 2014 Mar 17.


Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation.

Goodson ML, Mengeling BJ, Jonas BA, Privalsky ML.

J Biol Chem. 2011 Dec 30;286(52):44988-99. doi: 10.1074/jbc.M111.291625. Epub 2011 Nov 7.


Corepressors: custom tailoring and alterations while you wait.

Goodson M, Jonas BA, Privalsky MA.

Nucl Recept Signal. 2005;3:e003. Epub 2005 Oct 21.


SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways.

Jonas BA, Privalsky ML.

J Biol Chem. 2004 Dec 24;279(52):54676-86. Epub 2004 Oct 18.

Supplemental Content

Loading ...
Support Center